Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 9/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 8/20 | 0.41 |
| ▸ | ATR | Q13535 | 8/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 8/20 | 0.41 |
| ▸ | ATRIP | Q8WXE1 | 8/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 8/20 | 0.41 |
| ▸ | MTOR | P42345 | 3/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3600539 | 0.89 | PIK3CA (0.53) | PIK3CAPIK3CDCHEK1ATRPDCD1 | |
| SCHEMBL2814000 | 0.89 | PIK3CA (0.61) | PIK3CAPIK3CDCHEK1ATRPDCD1 | |
| SCHEMBL737810 | 0.88 | PIK3CA (0.55) | PIK3CAPIK3CDCHEK1ATRPDCD1 | |
| SCHEMBL3601002 | 0.87 | PIK3CA (0.52) | PIK3CAPIK3CDCHEK1ATRPDCD1 | |
| SCHEMBL3588712 | 0.87 | PIK3CD (0.51) | PIK3CAPIK3CDCHEK1ATRPDCD1 | |
| SCHEMBL3599239 | 0.86 | PIK3CD (0.51) | PIK3CAPIK3CDCHEK1ATRPDCD1 | |
| SCHEMBL3597669 | 0.85 | PIK3CA (0.49) | PIK3CAPIK3CDCHEK1ATRPDCD1 | |
| SCHEMBL3604751 | 0.82 | PIK3CA (0.52) | PIK3CAPIK3CDCHEK1ATRPDCD1 | |
| SCHEMBL4206266 | 0.81 | ATR (0.47) | PIK3CAPIK3CDATRATRIPMTOR | |
| SCHEMBL3605441 | 0.80 | PIK3CA (0.53) | PIK3CAPIK3CDCHEK1ATRPDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249131-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USED IN DISEASES LINKED TO MTOR KINASE AND/OR PI3K | ASTRAZENECA AB (SE) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249131-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USED IN DISEASES LINKED TO MTOR KINASE AND/OR PI3K | PIK3CA, MTOR, PIK3CD | PIK3CA 1/4885PIK3CD 3/4885CHEK1 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.